Skip to main content
Premium Trial:

Request an Annual Quote

Cognia Awarded NIGMS Grant to Build Protein Catabolism Database

NEW YORK, April 20 - Biological database developer Cognia has received a grant from the National Institutes of Health's National Institutes for General Medical Sciences to create a database on protein catabolism, the company said Friday.

The NIGMS awarded Cognia the one-year SBIR-Phase 1 grant to fund the development of a database that provides access to primary data and annotated information.

The company, which develops and distributes biological databases out of Mountain View, Calif., plans to initially focus on highly-regulated ubiquitin-proteasome pathways that are important for regulating intracellular protein levels.

Protein catabolism is becoming a major focus for drug targeting and lead identification, and is important in the exploration of pharmaceutical side effects, according to a company statement. The company was not immediately available for comment.

"Though not originally described by the central dogma of biology, protein turnover has emerged as equal in importance to transcription," said Cognia CEO David M. Rubin in a statement. "Cognia is building a system to provide biological context for the coming wave of proteomics data as well as standard RNA-based microarray data."

Christopher Larsen, a cell biologist at Harvard Medical School, will lead the effort to build the protein catabolism database.  
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.